Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hosing, C.
Right arrow Articles by Khouri, I.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosing, C.
Right arrow Articles by Khouri, I.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:450-459, 2002
© 2002 European Society for Medical Oncology

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma

C. Hosing+, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Körbling, T. Martin, N. T. Ueno, R.E. Champlin and I.F. Khouri

Departments of Blood and Marrow Transplantation and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Received 13 July 2001; revised 19 September 2001; accepted 23 October 2001.

Background

Several recent reports have suggested that patients with non-Hodgkin’s lymphomas (NHL) who undergo autologous stem cell transplantation (ASCT) are at increased risk of developing therapy-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML).

Patients and methods

We analyzed 493 patients with NHL who underwent ASCT at The University of Texas M.D. Anderson Cancer Center between January 1990 and August 1999.

Results

With a median follow-up time of 21 months after HDT, 22 patients developed persistent cytopenia in at least one cell line with morphologic or cytogenetic evidence of tMDS or tAML. Univariate analysis identified prior fludarabine therapy, bone marrow involvement with lymphoma, and total body irradiation (TBI) as significant risk factors for the development of tMDS/tAML (P <0.05). Multiple logistic regression analysis showed that TBI was independently associated with an increased risk of developing tMDS/tAML (P <0.01). Further analysis of the patients who received TBI revealed that patients receiving TBI in combination with cyclophosphamide and etoposide were more likely to develop tMDS/tAML than those who received TBI with cyclophosphamide or thiotepa (P <0.01). The median survival of patients developing tMDS/tAML was 7.5 months (range 0–32 months).

Conclusions

TBI, especially when used in combination with cyclophosphamide and etoposide as the pretransplant conditioning regimen, is a significant risk factor for the development of tMDS/tAML.

Key words: autologous transplantation, non-Hodgkin’s lymphoma, therapy-related acute myelogenous leukemia, therapy-related myelodysplasia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Y. Mudie, A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, P. J. Hoskin, and D. C. Linch
Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study
J. Clin. Oncol., April 1, 2006; 24(10): 1568 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al.
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
Ann. Onc., October 1, 2004; 15(10): 1484 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. A. Morrison
In Reply:
J. Clin. Oncol., October 1, 2003; 21(19): 3709 - 3710.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin, and I. F. Khouri
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
Ann. Onc., May 1, 2003; 14(5): 737 - 744.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.